A subset of breast cancer predisposes to brain metastasis

Medical Molecular Morphology

Volumn 44, Issue 1, 2011, Pages 15-20

  Shao, Mu Min ^a   Liu, Jun ^b   Vong, Joaquim S ^c   Niu, Yun ^b   Germin, Barbara ^d   Tang, Ping ^d   Chan, Anthony W H ^c   Lui, Philip C W ^c   Law, Bonita K B ^e   Tan, Puay Hoon ^f   Tse, Gary M ^c  

^a GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e Union Hospital   (Hong Kong)

^f SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Basal; Breast; Carcinoma; HER2; Metastasis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; PROTEIN P63; VASCULOTROPIN RECEPTOR;

ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER GRADING; CANCER INCIDENCE; CANCER RISK; CANCER SUSCEPTIBILITY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; BRAIN NEOPLASMS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; HUMANS; KERATIN-5; KERATIN-6; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MEMBRANE PROTEINS; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 79957438661     PISSN: 18601480     EISSN: 18601499     Source Type: Journal    
DOI: 10.1007/s00795-010-0495-2     Document Type: Article

References (54)

1. Lin NU, Bellon JR, Winer EP (2004) CNS metastases in breast cancer. J Clin Oncol 22:3608-3617 (Pubitemid 41103668)
2. Crivellari D, Pagani O, Veronesi A, Lombardi D, Nolè F, Thürlimann B, Hess D, Borner M, Bauer J, Martinelli G, Graffeo R, Sessa C, Goldhirsch A; International Breast Cancer Study Group (2001) High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann Oncol 12:353-356 (Pubitemid 32288692)
3. Ryberg M, Nielsen D, Osterlind K, Andersen PK, Skovsgaard T, Dombernowsky P (2005) Predictors of central nervous system metastasis in patients with metastatic breast cancer. A competing risk analysis of 579 patients treated with epirubicin-based chemotherapy. Breast Cancer Res Treat 91:217-225 (Pubitemid 40896568)
4. Abali H, Celik I (2002) High incidence of central nervous system involvement in patients with breast cancer treated with epirubicin and docetaxel. Am J Clin Oncol 25:632-633 (Pubitemid 35453676)
5. Kosmas C, Malamos NA, Tsavaris NB, Stamataki M, Stefanou S, Gregoriou A, Rokana S, Vartholomeou M, Antonopoulos MJ (2002) Leptomeningeal carcinomatosis after major remission to taxane-based front-line therapy in patients with advanced breast cancer. J Neurooncol 56:265-273 (Pubitemid 34476997)
6. Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer (Phila) 97:2972-2977 (Pubitemid 36676250)
7. Weil RJ, Palmieri DC, Bronder JL, Stark AM, Steeg PS (2005) Breast cancer metastasis to the central nervous system. Am J Pathol 167:913-920 (Pubitemid 41416243)
8. Duchnowska R, Szczylik C (2005) Central nervous system metastases in breast cancer patients administered trastuzumab. Cancer Treat Rev 31:312-318 (Pubitemid 41001678)
9. Clayton AJ, Danson S, Jolly S, Ryder WD, Burt PA, Stewart AL, Wilkinson PM, Welch RS, Magee B, Wilson G, Howell A, Wardley AM (2004) Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 91:639-643 (Pubitemid 39141617)
10. Lee YT (1983) Breast carcinoma: pattern of metastasis at autopsy. J Surg Oncol 23:175-180 (Pubitemid 13035296)
11. Tsukada Y, Fouad A, Pickren JW, Lane WW (1983) Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer (Phila) 52:2349-2354 (Pubitemid 14205961)
12. Carey LA, Ewend MG, Metzger R, Sawyer L, Dees EC, Sartor CI, Moore DT, Graham ML (2004) Central nervous system metastases in women after multimodality therapy for high risk breast cancer. Breast Cancer Res Treat 88:273-280 (Pubitemid 40137306)
13. Evans AJ, James JJ, Cornford EJ, Chan SY, Burrell HC, Pinder SE, Gutteridge E, Robertson JF, Hornbuckle J, Cheung KL (2004) Brain metastases from breast cancer: identification of a high-risk group. Clin Oncol 16:345-349 (Pubitemid 38967255)
14. Gonzalez-Angulo AM, Cristofanilli M, Strom EA, Buzdar AU, Kau SW, Broglio KR, Smith TL, Hortobagyi GN (2004) Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment. Cancer (Phila) 101:1760-1766 (Pubitemid 39314738)
15. Miller KD, Weathers T, Haney LG, Timmerman R, Dickler M, Shen J, Sledge GW Jr (2003) Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann Oncol 14:1072-1077 (Pubitemid 36950171)
16. Maki DD, Grossman RI (2000) Patterns of disease spread in metastatic breast carcinoma: influence of estrogen and progesterone receptor status. Am J Neuroradiol 21:1064-1066 (Pubitemid 30390543)
17. Samaan NA, Buzdar AU, Aldinger KA, Schultz PN, Yang KP, Romsdahl MM, Martin R (1981) Estrogen receptor: a prognostic factor in breast cancer. Cancer (Phila) 47:554-560 (Pubitemid 11174922)
18. Tsuda H, Takarabe T, Hasegawa F, Fukutomi T, Hirohashi S (2000) Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am J Surg Pathol 24:197-202 (Pubitemid 30078708)
19. Rakha EA, Putti TC, Abd El-Rehim DM, Paish C, Green AR, Powe DG, Lee AH, Robertson JF, Ellis IO (2006) Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol 208:495-506 (Pubitemid 43329336)
20. Laakso M, Tanner M, Nilsson J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Bergh J, Isola J (2006) Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin Cancer Res 12:4185-4191
21. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10:5367-5374 (Pubitemid 39100473)
22. Gaedcke J, Traub F, Milde S, Wilkens L, Stan A, Ostertag H, Christgen M, von Wasielewski R, Kreipe HH (2007) Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer. Mod Pathol 20:864-870 (Pubitemid 47077270)
23. Yonemori K, Tsuta K, Shimizu C, Hatanaka Y, Hashizume K, Ono M, Nakanishi Y, Hasegawa T, Miyakita Y, Narita Y, Shibui S, Fujiwara Y (2008) Immunohistochemical profiles of brain metastases from breast cancer. J Neurooncol 90:223-228
24. Hicks DG, Short SM, Prescott NL, Tarr SM, Coleman KA, Yoder BJ, Crowe JP, Choueiri TK, Dawson AE, Budd GT, Tubbs RR, Casey G, Weil RJ (2006) Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal 20 cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol 30:1097-1104 (Pubitemid 44299342)
25. Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R (2006) Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer (Phila) 107:696-704 (Pubitemid 44232661)
26. Grupka NL, Lear-Kaul KC, Kleinschmidt-DeMasters BK, Singh M (2004) Epidermal growth factor receptor status in breast cancer metastases to the central nervous system. Comparison with HER-2/neu status. Arch Pathol Lab Med 128:974-979 (Pubitemid 39202242)
27. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology (Oxf) 19:403-410
28. Boogerd W (1996) Central nervous system metastasis in breast cancer. Radiother Oncol 40:5-22 29.
29. DiStefano A, Yong Yap Y, Hortobagyi GN, Blumenschein GR (1979) The natural history of breast cancer patients with brain metastases. Cancer (Phila) 44:1913-1918 (Pubitemid 10141974)
30. Posner JB (1977) Management of central nervous system metastases. Semin Oncol 4:81-91 (Pubitemid 8071003)
31. Cairncross JG, Kim JH, Posner JB (1980) Radiation therapy for brain metastases. Ann Neurol 7:529-541 (Pubitemid 10018360)
32. Lee SS, Ahn JH, Kim MK, Sym SJ, Gong G, Ahn SD, Kim SB, Kim WK (2008) Brain metastases in breast cancer: prognostic factors and management. Breast Cancer Res Treat 111:523-530
33. Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, Markesbery WR, Macdonald JS, Young B (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322:494-500 (Pubitemid 20067825)
34. Hines SL, Vallow LA, Tan WW, McNeil RB, Perez EA, Jain A (2008) Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer. Ann Oncol 19:1561-1565
35. Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, Crivellari D, Fey MF, Murray E, Pagani O, Simoncini E, Castiglione-Gertsch M, Gelber RD, Coates AS, Goldhirsch A; International Breast Cancer Study Group (IBCSG) (2006) Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 17:935-944 (Pubitemid 43778983)
36. Stemmler HJ, Kahlert S, Siekiera W, Untch M, Heinrich B, Heinemann V (2006) Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 15:219-225
37. Shmueli E, Wigler N, Inbar M (2004) Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment. Eur J Cancer 40:379-382 (Pubitemid 38121275)
38. Stemmler HJ, Heinemann V (2008) Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challenge. Oncologist 13:739-750
39. Pestalozzi BC, Brignoli S (2000) Trastuzumab in CSF. J Clin Oncol 18:2349-2351
40. Lin NU, Winer EP (2007) Brain metastases: the HER2 paradigm. Clin Cancer Res 13:1648-1655 (Pubitemid 46952930)
41. Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ, Harris AL (1987) Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1: 1398-1402 (Pubitemid 17078859)
42. Tsutsui S, Ohno S, Murakami S, Kataoka A, Kinoshita J, Hachitanda Y (2003) Prognostic value of the combination of epidermal growth factor receptor and c-erbB-2 in breast cancer. Surgery (St. Louis) 133:219-221 (Pubitemid 36407987)
43. Nicholson S, Sainsbury JR, Halcrow P, Chambers P, Farndon JR, Harris AL (1989) Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer. Lancet 1:182-185 (Pubitemid 19038803)
44. Luck AA, Evans AJ, Green AR, Rakha EA, Paish C, Ellis IO (2008) The influence of basal phenotype on the metastatic pattern of breast cancer. Clin Oncol 20:40-45
45. Mobbs BG, Fish EB, Pritchard KI, Oldfi eld G, Hanna WH (1986) Estrogen and progesterone receptor content of primary and secondary breast carcinoma: influence of time and treatment. Eur J Cancer Clin Oncol 23:819-826
46. Santinelli A, Pisa E, Stramazzotti D, Fabris G (2008) HER-2status discrepancy between primary breast cancer and metastatic sites: impact on target therapy. Int J Cancer 122:99-104
47. Masood S, Bui MM (2000) Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study. Ann Clin Lab Sci 30:259-265 (Pubitemid 30620800)
48. Shimizu C, Fukutomi T, Tsuda H, Akashi-Tanaka S, Watanabe T, Nanasawa T, Sugihara K (2000) c-erb B2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues. J Surg Oncol 73:17-20 (Pubitemid 30067528)
49. Kamby C, Rasmussen BB, Kristensen B (1989) Oestrogen receptor status of primary breast carcinomas and their metastases. Relation to pattern of spread and survival after recurrence. Br J Cancer 60:252-257 (Pubitemid 19207850)
50. Li BD, Byskosh A, Molteni A, Duda RB (1994) Estrogen and progesterone receptor concordance between primary and recurrent breast cancer. J Surg Oncol 57:71-77 (Pubitemid 24299653)
51. Lear-Kaul KC, Yoon HR, Kleinschmidt-DeMasters BK, McGavran L, Singh M (2003) Her-2/neu status in breast cancer metastases to the central nervous system. Arch Pathol Lab Med 127: 1451-1457 (Pubitemid 37370391)
52. Elyse EL, Eleanor LG, Deborah AB, Robbin B, Sue H (2005) Impact of metastatic estrogen receptor and progesterone receptor status on survival. Breast Cancer Res Treat 90:62-70
53. Cui X, Schiff R, Arpino G, Osborne CK, Lee AV (2005) Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 23:7721-7735 (Pubitemid 46291836)
54. Zidan J, Dashkovsky I, Stayerman C, Basher W, Cozacov C, Hadary A (2005) Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 93:552-556 (Pubitemid 43079998)